Novo CEO says weight-loss pills could capture 50% by 2030
Novo Nordisk CEO Mike Doustdar tells Reuters that weight-loss pills could take up to half of the global obesity-drug market by 2030 as the company prepares for a shift away from weekly injections.
Novo Nordisk chief executive Mike Doustdar told Reuters on Tuesday that weight-loss pills could take as much as half of the global obesity drug market by 2030, as the Danish drugmaker prepares for a shift away from weekly injections. Doustdar said Novo was preparing for that transition.